Premium
P2‐065: A megalin polymorphism associated with increased Alzheimer's disease risk
Author(s) -
Vargas Teo,
Bullido Maria J.,
Martinez Ana,
Antequera Desiree,
Clarimon Jordi,
RosichEstrago Marcel,
MartinRequero Angeles,
VilellaCuadrado Elisabet,
Frank Ana,
Lleo Alberto,
MolinaPorcel Laura,
Blesa Rafael,
GomezIsla Teresa,
BermejoPareja Felix,
Valdivieso Fernando,
Carro Eva
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.04.375
Subject(s) - genotype , single nucleotide polymorphism , promoter , disease , context (archaeology) , biology , alzheimer's disease , tau protein , gene , polymorphism (computer science) , genetics , medicine , endocrinology , gene expression , paleontology
compared to AD group: 115.3632.1vs 88.9613.2 mg/dL (p<0.0001), and controls 90.2612.4 mg/dL (p<0.0001). No difference was recorded in mean TG or FPG between AD patients and controls. When classified by decennial age strata, a same pattern of results was recorded for all subgroups. Across dementia staging by CDR, mean cholesterol, triglycerides, and glucose levels were significantly higher in VaD compared to AD group across all CDR subgroups. Differences persisted when VaD patients were classified by disease duration subgroups. Conclusions: These results suggest that there are substantial differences in the studied biochemical parameters, which may prove valuable in helping to distinguish appreciatively subjects with AD from those with VaD, at any time point of the disease course, i.e. mild vs frank hypercholesterolemia, normal vs normal or higher triglyceridemia, normal vs normal or higher glycemia, in AD vs VaD respectively.